1. Introduction {#s0005}
===============

Nanotechnology has emerged as an attractive research technology with potential adaptability in several areas including agriculture, biomedical engineering, cosmetology, disease diagnosis, drug therapy and energy. Nanotechnology has been used in several industries to develop materials with substantially improved properties, functionalities and utilities. The pharmaceutical, biotechnology, biomedical engineering and material sciences industries have developed nanotechnology-based materials, such as nanocrystals ([@b0220]), carbon nanotubes ([@b0155]), quantum dots ([@b0075]), metallic nanoparticles ([@b0160]) and polymeric nanoparticles ([@b0130]) for use as diagnostics, therapeutics or drug delivery carriers. Among these nanomaterials, nanoparticles have been studied extensively as therapeutics or as nano-therapeutic carriers for small or large drug molecules, including genetic materials and biologics such as DNA ([@b0135]), RNA ([@b0180]), proteins ([@b0145]) and enzymes ([@b0190]).

Nanoparticles are nano-sized objects of any shape where all three dimensions occupy 1--100 nm ([@b0020]). This ultrafine size imparts unique physicochemical properties that are not exhibited by bulk material. Nanoparticle preparations are generally administered intravenously. However, rapid clearance by the reticuloendothelial system decreases their circulatory half-life, and the formulated drug is often eliminated before reaching its target. Oral administration of nanoparticles is also problematic due to negligible oral absorption and cellular uptake that are likely caused by the absorption of the nanoparticles through passive transport. Absorption and uptake are significantly influenced by nanoparticle size, with smaller nanoparticles exhibiting better oral absorption than bigger ones ([@b0050], [@b0060], [@b0085]).

Metallic nanoparticles have been investigated extensively due to easy fabrication, relatively small sizes with small polydispersity index when compared with polymeric nanoparticles. The very tiny metallic particles with the corresponding very large effective surface area are highly reactive but potentially toxic as well ([@b0115], [@b0140]). However, gold nanoparticles have been found to be biocompatible and comparatively less toxic ([@b9000]). Gold nanoparticles are extensively investigated as nanotherapeutics, diagnostics and imaging probes ([@b0100], [@b0200]), intracellular drug delivery carriers ([@b0065]), intracellular gene regulators ([@b0205]) and tumor-targeting therapeutics ([@b0170]). Gold nanoparticles are also excellent conductors of electrical and thermal energy, making it possible to administer non-invasive radiofrequency irradiation with sufficient heat to kill tumor cells ([@b0100], [@b9030]).

Gold nanoparticles can be fabricated easily in very small size such as 1 nm with a very small polydispersity index employing simple and rapid preparation method that is commercially viable. In addition, gold nanoparticles possess characteristics that make them suitable for pharmacokinetic evaluation after oral administration, such as high electron density, low background concentration and poor solubility in biological matrices ([@b0090]).

We have previously investigated the oral bioavailability of gold nanoparticles in rats, wherein, gold nanoparticles of approximately 5 nm were coated with 1, 2 and 5 kDa of polyethylene glycol (PEG) ([@b9005]). PEG coating was supposed to enhance the oral bioavailability of the nanoparticles as it known to minimize the immune system recognition and elimination, thereby increasing circulatory half-life ([@b9005]). Furthermore, PEG coating has also been reported to minimize the agglomeration of nanoparticles ([@b0090]). Bioavailability of low molecular weight PEG coated gold nanoparticles (1 kDa of PEG) was approximately 3--4 fold higher than those coated with 2 and 5 kDa of PEG. However, it was still too low to produce any clinically significant effect. Therefore, we proposed coating of gold nanoparticles with chitosan, a polysaccharide-based muco-adhesive polymer with absorption enhancement capabilities, to enhance their oral bioavailability.

Chitosan is a natural nontoxic biodegradable macromolecule consisted of glucosamine and N-acetyl-glucosamine ([@b0095], [@b0080], [@b0225]). It has been used to formulate particulate systems, such as liposomes and nanoparticles, wherein drug candidates are encapsulated in the polymer membrane. Chitosan's positively charged surface tends to bind to negatively charged cell membranes. It binds with occludin, redistributes F-actin, disrupts the plasma membrane, and decreases the trans-epithelial electrical resistance (TEER) of cells thereby increasing transcellular and paracellular diffusion of the enclosed drugs ([@b0015], [@b0040], [@b0215], [@b0210], [@b0240]). Chitosan's muco-adhesive properties that enhance the diffusion or absorption of the enclosed drugs by prolonging the gastric residence time ([@b0025], [@b0120]). Due to low toxicity, biodegradability, pH responsiveness and muco-adhesion, chitosan coated systems have been used as effective oral delivery carriers for numerous drugs ([@b0005], [@b0185]), proteins and peptides ([@b0010], [@b0105], [@b0165], [@b0235], [@b0250]) and non-viral genes, DNA and nucleic acid vaccines ([@b0035], [@b0175]).

To the best of our knowledge, chitosan coating of AuNPs to improve oral bioavailability has not been reported. Some chitosan derivatives have been used to coat AuNPs or gold nanorods for imaging, probing, or anticancer applications ([@b0030], [@b0045], [@b0230]). [@b0030] reported chitosan-coated gold nanoparticles as a sensitive probe for the recognition of heparin. Doxorubicin loaded and thiolated-chitosan coated Gold nanorods were evaluated in vitro for their combined chemical and photothermal effects on cancer cell lines ([@b0045]). In another report, glycol chitosan coated gold nanoparticles (GC-AuNPs) were evaluated for tumor targeting using computed tomography. The biodistribution of the GC-AuNPs was compared with heparin-coated nanoparticles ([@b0230]).

The aim of this study was to investigate the influence of chitosan coating on the pharmacokinetics and bioavailability of nanoparticles after administering coated or uncoated nanoparticles in the rats. We employed the classical method that involved comparisons of blood concentrations of gold (Cmax) and area under the curve (AUC) after oral & intravenous administrations.

2. Methodology {#s0010}
==============

2.1. Preparation and coating of gold nanoparticles {#s0015}
--------------------------------------------------

Gold nanoparticles of approximately 3 nm were fabricated by the method reported elsewhere ([@b9005]). The nanoparticles, which formed rapidly upon addition of the sodium borohydride, were then allowed to stand overnight prior to coating. Chitosan (Aldrich) was dissolved in deionized water until saturated. The prepared gold nanoparticles were incubated with 1 mL of the saturated chitosan solution under vigorous stirring. The coated nanoparticles were acidified using 0.1 M HCl (Fisher ACS Grade) until the suspension of chitosan-coated nanoparticles (C-AuNPs) was stable.

2.2. Nanoparticle characterization {#s0020}
----------------------------------

Nanoparticles were characterized for size, shape and zeta potential similarly as described elsewhere ([@b9005]). Particle size (hydrodynamic radius) and size-distribution were investigated by Nanotrac with DLS technique (Microtrac, Inc., Montgomeryville, PA), whereas zeta potential was evaluated by using ZetaPlus, Brookhaven. The size and shape of AuNPs were further confirmed by transmission electron microscope (Hitachi H7000).

2.3. In vivo study {#s0025}
------------------

In vivo pharmacokinetic bioavailability of coated and uncoated gold nanoparticles were investigated in Male Wistar rats as per the approved protocol by the University of Florida Institutional Animal Care and Use Committee. Rats were treated caringly as per the guidance provided in the *Guide for the Care and Use of Laboratory Animals* ([@b9025]). All the animals between 180 and 220 g, were divided in two groups of five each and caged individually in the standard environment (18--26 °C, and 30--70% humidity), with free access to water and standard diet. Animals in group one received 8 mg/kg body weight of coated nanoparticles through oral gavage after 12 h of fasting which continued two hours post dose. Animals in group two received 0.8 mg/kg body weight of coated gold nanoparticles via the jugular cannula. Blood samples were extracted at 0, 0.5, 1, 2, 4, 8, 12, 24 and 48 h post dose.

2.4. Determination of gold concentrations in blood {#s0030}
--------------------------------------------------

The concentration of gold nanoparticles in blood was determined by Inductive coupled plasma mass spectrometry (Thermo Electron X Series II ICP-MS, Thermo Scientific, West Palm Beach, FL) Briefly, 0.2 mL blood was processed with nitric acid, Hydrogen peroxide and aqua regia, followed by filtration, 0.22 mm PTFE and determination using indium as internal standard ([@b9005]).

2.5. Estimation of bioavailability of gold nanoparticles {#s0035}
--------------------------------------------------------

Bioavailability of gold nanoparticles were estimated using pharmacokinetic parameters such as maximum blood concentration (Cmax) and area under the curve (AUC) of blood concentration versus time profiles. Non-compartmental analysis of concentration versus time data was done by using Phoenix (Pharsight, Mountain View, CA). Oral bioavailability of gold nanoparticles (F) was determined by using the formula given below$$\text{F} = \text{AUCpo} \times \text{Dose}\,\text{iv}/\text{AUC}\,\text{iv} \times \text{Dose}\,\text{po}$$

2.6. Statistical evaluation {#s0040}
---------------------------

Statistical evaluation of concentration data were carried out on Prism (GraphPad Software Inc., La Jolla, CA). The concentrations of gold in the blood are presented as a mean ± SD. One-way ANOVA and Tukey's test were used to determine the differences that were considered as statistically significant (p value ≤ 0.05).

3. Results {#s0045}
==========

3.1. Size, shape and morphology of gold nanoparticle {#s0050}
----------------------------------------------------

The chitosan coated gold nanoparticles were found to have an average size of 3 ± 1.2 nm. Zeta potentials for the C-AuNPs in water were indistinguishable from the neutral measurement: 1.3 ± 0.9 mV. Size and shape of gold nanoparticles were confirmed by TEM ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Particle Characterization: Transmission electron micrograph (TEM) of chitosan coated 5 nm particles. One-hundred particles were measured to determine the average primary size to be 3 ± 1.2 nm.

3.2. Oral bioavailability of gold nanoparticles {#s0055}
-----------------------------------------------

As the animals in this study received either oral or intravenous doses of the nanoparticles, the comparative oral bioavailability was estimated as the ratio of average AUCpo and AUCiv calculated from gold concentration-time profiles, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, respectively. Results of pharmacokinetic evaluations are presented in the [Table 1](#t0005){ref-type="table"}. The oral bioavailability for the C-AuNPs was estimated as 2.46%.Fig. 2The concentration vs time profile of IV data of 5 nm AuNPs of chitosan coated. Gold concentration was measured using ICP-MS. Data are presented as average ± SD.Fig. 3The concentration vs time profile of ORAL data of 5 nm AuNPs of chitosan coated. Gold concentration was measured using ICP-MS. Data are presented as average ± SD.Table 1Pharmacokinetic parameters of gold nanoparticles.RouteNT 1/2 (h)C max (ng/ml)AUCcall (h\*ng/ml)AUCINF (h\*ng/ml)Vd (ml)CL (ml/h)Tmax (h)IV (0.8 mg/kg)N19.381170.6698.1824.83282242.4N28.221369.6750.3840.42832.8237.9N310.681528.2976.41191.42586.8167.8**Mean9.431356.1808.27952.16672900.5216.03SD1.230179.179147.918207.329352.641.831**  ORAL (8 mg/kg)28.116.54105237.7341283.38414.661350.025.6192.1312.93461210.463911218.744.5284.91151.85356243.713170.211**Mean32.295.5794.003234.16386,2459325.212SD16.051.01110.17980.59865350.83480.10.12**  **F_AUCINF2.46%**[^1]

4. Discussions {#s0060}
==============

Bioavailability assessments of metal-based nanoparticles have mainly utilized nanoparticle measurements in matrices such as urine and feces. However, biliary excretion of metallic nanoparticles are documented, which could lead to inaccurate bioavailability estimations ([@b0090], [@b9015]). There are very limited number of studies that utilized comparative AUC/Cmax after oral and intravenous doses for estimating oral bioavailability. [@b0150] and [@b9020] estimated oral bioavalibilities of ZnO nanoparticles and citrate-coated silver nanoparticles respectively in the rats.

[@b0090], reported oral bioavailability gold nanoparticles of about 23 nm with or without coating with PEG in mice. However, they did not report pharmacokinetic parameters as they collected samples form blood and tissues at three time points only (6, 12, 24 h post dose). Moreover, they did not compare it with IV administration, rather compared it with the amount they administered. They found significantly low bioavailability of uncoated gold nanoparticles due to substantial agglomeration when compared with coated ones which prevented agglomeration. However, oral bioavailability of coated gold nanoparticles was still very low (1% of administered dose). One of the reasons of low oral bioavalibilities of PEG coated particles has been attributed to the reduction in opsonization due to the presence of PEG thus leading to minimized phagocytosis or cellular uptake ([@b0070]). Furthermore, the extent of cellular uptake is reported to be dependent on the size of the particles, and smaller particles are absorbed better than larger particles ([@b0085], [@b0245]).

We have already investigated the effect of PEG coating on the oral bioavailability of gold nanoparticles ([@b9005]). We found an inverse relationship between the PEG molecular weight used in the coating and the oral bioavailability achieved. However, the highest oral bioavailability achieved with 1 kDa PEG coating was only 0.1%. The present investigation reported the oral bioavailability of Chitosan coated gold nanoparticles (C-AuNPs) by comparing AUCinf after intravenous and oral administration of 0.8 and 8 mg/kg body weight of rats respectively. Chitosan, a mucoadhesive polymer, is known to enhance permeation or absorption thus improving oral bioavailability ([@b0055]). The chitosan-coating resulted in 2.46% oral bioavailability, approximately 25-fold higher than that achieved with the PEG coatings.

5. Conclusions {#s0065}
==============

The estimation of oral bioavailability of the chitosan coated gold nanoparticles in rats by using conventional method wherein pharmacokinetics parameters such as Cmax, AUC, Vd, CL etc. following oral administration were compared with those of achieved following intravenous administration. Results obtained in this report were promising as compared to our previous reports. However, it is still too low to depict any clinically significant effect for therapies. We plan to have more investigation on the chitosan coating and agglomeration of the gold nanoparticles in near future.
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[^1]: N- number of animals, T½: half-life; Cmax: Maximum concentration of gold nanoparticles in blood, **AUCcall:** Area under curve calculated till last quantifiable time point; **AUCINF:** Area under curve extrapolated till infinite time; CL: Clearance; Vd: volume of distribution. **F_AUCINF**: bioavailability calculated from Area Under the Plasma Concentration-Time Profile from Time 0 to Infinity.
